{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:11:09Z","timestamp":1789233069547,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96065-9","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T16:16:41Z","timestamp":1744388201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Tessa","family":"van Elst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjaak","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart P.","family":"Wijsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Luijendijk-de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M.","family":"van Dodewaard-de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter L.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Lavalaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafak","family":"Aluwini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Yakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F. A.","family":"Mulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiko J.","family":"Bloemendal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul A.","family":"van Basten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"10162","key":"96065_CR1","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392 (10162), 2353\u20132366 (2018).","journal-title":"Lancet"},{"issue":"8","key":"96065_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl. J. Med. 373 (8), 737\u2013746 (2015).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"96065_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl. J. Med. 377 (4), 352\u2013360 (2017).","journal-title":"N Engl. J. Med."},{"issue":"32","key":"96065_CR4","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37 (32), 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"96065_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi, K. N. et al. Apalutamide for metastatic, Castration-sensitive prostate cancer. N Engl. J. Med. 381 (1), 13\u201324 (2019).","journal-title":"N Engl. J. Med."},{"issue":"2","key":"96065_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl. J. Med. 381 (2), 121\u2013131 (2019).","journal-title":"N Engl. J. Med."},{"issue":"10231","key":"96065_CR7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395 (10231), 1208\u20131216 (2020).","journal-title":"Lancet"},{"issue":"7","key":"96065_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","volume":"24","author":"CL Vale","year":"2023","unstructured":"Vale, C. L. et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 24 (7), 783\u2013797 (2023).","journal-title":"Lancet Oncol."},{"issue":"5","key":"96065_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","volume":"9","author":"B Hoeh","year":"2023","unstructured":"Hoeh, B. et al. Triplet or doublet therapy in metastatic Hormone-sensitive prostate cancer: updated network Meta-analysis stratified by disease volume. Eur. Urol. Focus. 9 (5), 838\u2013842 (2023).","journal-title":"Eur. Urol. Focus"},{"issue":"5","key":"96065_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz, I. B. et al. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: A living systematic review and network Meta-analysis. JAMA Oncol. 9 (5), 635\u2013645 (2023).","journal-title":"JAMA Oncol."},{"issue":"1","key":"96065_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.eururo.2022.10.005","volume":"83","author":"N Ayati","year":"2023","unstructured":"Ayati, N., Herrmann, K., Fanti, S., Murphy, D. G. & Hofman, M. S. More accurate imaging is not stage migration: time to move from hubble to Webb in Hormone-sensitive prostate cancer. Eur. Urol. 83 (1), 6\u20139 (2023).","journal-title":"Eur. Urol."},{"issue":"2","key":"96065_CR12","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/j.clgc.2021.11.018","volume":"20","author":"J Zheng","year":"2022","unstructured":"Zheng, J. et al. Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. Clin. Genitourin. Cancer. 20 (2), e151\u2013e7 (2022).","journal-title":"Clin. Genitourin. Cancer"},{"issue":"7","key":"96065_CR13","first-page":"570","volume":"4","author":"D Subedi","year":"2016","unstructured":"Subedi, D. Explanatory sequential mixed method design as the third research community of knowledge claim. Am. J. Educational Res. 4 (7), 570\u2013577 (2016).","journal-title":"Am. J. Educational Res."},{"issue":"8","key":"96065_CR14","doi-asserted-by":"publisher","first-page":"e072572","DOI":"10.1136\/bmjopen-2023-072572","volume":"13","author":"T van Elst","year":"2023","unstructured":"van Elst, T. et al. TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment. BMJ Open. 13 (8), e072572 (2023).","journal-title":"BMJ Open."},{"issue":"2","key":"96065_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun, V. & Clarke, V. Using thematic analysis in psychology. Qualitative Res. Psychol. 3 (2), 77\u2013101 (2006).","journal-title":"Qualitative Res. Psychol."},{"key":"96065_CR16","doi-asserted-by":"crossref","unstructured":"Groenland, E. A. G. & Dana, L. P. Qualitative methodologies and data collection methods. toward increased rigour in management research (World Scientific Publishing Company, 2019).","DOI":"10.1142\/11449"},{"key":"96065_CR17","unstructured":"Guidelines, N. V. U. (Prostate Cancer). (2023)."},{"issue":"2","key":"96065_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur. Urol. 79 (2), 263\u2013282 (2021).","journal-title":"Eur. Urol."},{"issue":"3","key":"96065_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bco2.73","volume":"2","author":"S Aluwini","year":"2021","unstructured":"Aluwini, S. et al. M1a prostate cancer: results of a Dutch multidisciplinary consensus meeting. BJUI Compass. 2 (3), 159\u2013168 (2021).","journal-title":"BJUI Compass"},{"issue":"1","key":"96065_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euo.2022.10.002","volume":"6","author":"HA de Barros","year":"2023","unstructured":"de Barros, H. A. et al. Role of local and\/or Metastasis-directed therapy in patients with Hormone-sensitive M1a prostate Cancer-a systematic review. Eur. Urol. Oncol. 6 (1), 16\u201327 (2023).","journal-title":"Eur. Urol. Oncol."},{"issue":"4","key":"96065_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","volume":"7","author":"A Ali","year":"2021","unstructured":"Ali, A. et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol. 7 (4), 555\u2013563 (2021).","journal-title":"JAMA Oncol."},{"issue":"10","key":"96065_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer, E. M. et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 21 (10), 1067\u20131096 (2023).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"96065_CR23","unstructured":"Gillessen, S. et al. Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the advanced prostate cancer consensus conference (APCCC) 2022. Eur J Cancer. 185 178\u2013215. (2023)."},{"key":"96065_CR24","unstructured":"Bossi, A. F. et al. K. Prostate irradiation in men with De Novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design. ASCO: J. Clinical Oncol."},{"key":"96065_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","volume":"176","author":"T Zilli","year":"2022","unstructured":"Zilli, T. et al. Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol. 176, 199\u2013207 (2022).","journal-title":"Radiother Oncol."},{"issue":"29","key":"96065_CR26","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek, M. P. et al. Long-Term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J. Clin. Oncol. 40 (29), 3377\u20133382 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"96065_CR27","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke, N. W. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol. 30 (12), 1992\u20132003 (2019).","journal-title":"Ann. Oncol."},{"key":"96065_CR28","unstructured":"Coenen, J. G. & de Reijke, J. T. Advies landelijke Richtlijnwerkgroep prostaatcarcinoom. Expert opinion. Medische Oncologie  43. (2018)."},{"issue":"3","key":"96065_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","volume":"7","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: A systematic review and network meta-analysis. JAMA Oncol. 7 (3), 412\u2013420 (2021).","journal-title":"JAMA Oncol."},{"issue":"3","key":"96065_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.eururo.2019.09.004","volume":"77","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen, N. J. et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: A systematic review and network Meta-analysis. Eur. Urol. 77 (3), 365\u2013372 (2020).","journal-title":"Eur. Urol."},{"issue":"4","key":"96065_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bju.15507","volume":"129","author":"K Mori","year":"2022","unstructured":"Mori, K. et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int. 129 (4), 423\u2013433 (2022).","journal-title":"BJU Int."},{"issue":"8","key":"96065_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.21.00728","volume":"40","author":"HL Rush","year":"2022","unstructured":"Rush, H. L. et al. Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial. J. Clin. Oncol. 40 (8), 825\u2013836 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"96065_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki, D. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur. Urol. 86 (2), 164\u2013182 (2024).","journal-title":"Eur. Urol."},{"key":"96065_CR34","unstructured":"Schaeffer, E. M. NCCN Guidelines Version 4.2024 Prostate cancer. (2024)."},{"issue":"2","key":"96065_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 79 (2), 243\u2013262 (2021).","journal-title":"Eur. Urol."},{"issue":"3","key":"96065_CR36","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00259-023-06490-z","volume":"51","author":"M Bauckneht","year":"2024","unstructured":"Bauckneht, M. et al. The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging. 51 (3), 864\u2013870 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"96065_CR37","doi-asserted-by":"crossref","unstructured":"Morgans, A. R. et al. Y, Eidelberg Spratt, D. Interaction ofage and benefit of treatment intensification in advanced prostate cancer: an aggregate meta-analysis of 14 randomized trials. J. Clinical Oncol., 2024.","DOI":"10.1200\/JCO.2024.42.4_suppl.118"},{"issue":"10336","key":"96065_CR38","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet 399 (10336), 1695\u20131707 (2022).","journal-title":"Lancet"},{"issue":"12","key":"96065_CR39","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Darolutamide and survival in metastatic, Hormone-Sensitive prostate cancer. N Engl. J. Med. 386 (12), 1132\u20131142 (2022).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"96065_CR40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clgc.2022.11.001","volume":"21","author":"E Lambert","year":"2023","unstructured":"Lambert, E. et al. The changing landscape of systemic therapy in the treatment of synchronous metastatic Hormone-sensitive prostate cancer. Clin. Genitourin. Cancer. 21 (3), 415 (2023). e1- e8.","journal-title":"Clin. Genitourin. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96065-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96065-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96065-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T16:16:47Z","timestamp":1744388207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96065-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96065"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96065-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TE reports funding for research from Johnson & Johnson. NM reports grants, institutional and personal fees from Johnson & Johnson. Outside of the submitted work, NM reports grants and personal fees from MSD, AstraZeneca, Astellas, BMS, Pfizer and Bayer. DY reports Astellas consultancy fee. Other authors did not report any relevant conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"In accordance with Dutch legislation, studies of this nature are exempt from the review of a research ethics committee as the participants (i.e., the physicians) were not subjected to procedures or required to follow rules of behaviour. Therefore, this study was not submitted to an ethics committee\/ institutional review board for approval. After providing the physicians with adequate information, we considered their consent to complete the survey and participate in the focus groups as sufficient informed consent for the study. The physicians participating in the focus groups explicitly consented to the videotaping of the focus group proceedings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants consented for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"12500"}}